Hansa Biopharma reported its Q4 2024 earnings, revealing a larger-than-expected loss and lower-than-forecast revenue. The company posted an EPS of -4.08, significantly missing the forecast of -1.98, ...
Bristol-Myers Squibb (NYSE:BMY) reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings ...